Antisense oligonucleotides useful in treatment of Pompe disease
AssigneeErasmus University Medical Center Rotterdam
InventorsAtze Jacobus Bergsma, Erik van der Wal, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske van der Ploeg, Arnoldus Reuser
Life of this patent
Estimating the term…
Abstract
The present invention is directed to antisense oligomeric compounds that may be used in the treatment Pompe disease as well as method for modulating the splicing of the GAA gene and method to treat Pompe disease. Also pharmaceutical compositions comprising the antisense oligomeric compounds are part of the invention.
Claims7
A method of modulating splicing of GAA pre-mRNA in a cell comprising:
- contacting the cell with an antisense oligomeric compound targeting SEQ ID NO:1 or a single nucleotide polymorphism of SEQ ID NO:1, wherein the antisense oligomeric compound comprises a nucleic acid sequence selected from the group consisting of SEQ ID Nos:
- 2-33, 38-40, 47 and 92-97 or a sequence having at least 95% sequence identity thereto.
A method for treating Pompe disease in a patient comprising administering an effective amount of an antisense oligmeric compound targeting SEQ ID NO:1 or a single nucleotide polymorphism of SEQ ID NO:1, wherein the antisense oligomeric compound comprises a nucleic acid sequence selected from the group consisting of SEQ ID Nos:
- 2-33, 38-40, 47 and 92-97 or a sequence having at least 95% sequence identity thereto.
A method to restore the function of GAA in a cell wherein said method comprises the administration of an antisense oligmeric compound targeting SEQ ID NO:1 or a single nucleotide polymorphism of SEQ ID NO:1, wherein the antisense oligomeric compound comprises a nucleic acid sequence selected from the group consisting of SEQ ID Nos:
- 2-33, 38-40, 47 and 92-97 or a sequence having at least 95% sequence identity thereto.
A method of correcting abnormal gene expression in a cell, preferably a muscular cell, of a subject, the method comprising administering to the subject an antisense oligomeric compound targeting SEQ ID NO:1 or a single nucleotide polymorphism of SEQ ID NO:1, wherein the antisense oligomeric compound comprises a nucleic acid sequence selected from the group consisting of SEQ ID Nos:
- 2-33, 38-40, 47 and 92-97 or a sequence having at least 95% sequence identity thereto.
Dependencies are inferred from the claim text.